VericelVCEL -2.51%81 3-Year ROIIC % is 13.84 as of Dec. 2025, which is 22% above its 10-year median of 11.39. GuruFocus rates VCEL with a GF Score™ of 81/100 and a GF Value™ of $54.29 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,324 Biotechnology companies, Vericel ranks better than 62.84% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Vericel's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 13.84%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Vericel's 3-Year ROIIC % or its related term are showing as below:
VCEL's 3-Year ROIIC % is ranked better than 62.84% of 1324
companies
in the Biotechnology industry
Industry Median: -4.63
vs VCEL: 13.84
Vericel (NAS:VCEL) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Vericel 3-Year ROIIC % Related Terms
Vericel 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Vericel's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VCEL vs NRIX, MLYS, PHVS: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Vericel's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Vericel's 3-Year ROIIC % falls into.
Vericel's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 10.4984264 (Dec. 2025) - -17.058 (Dec. 2022) )
/
( 329.668 (Dec. 2025) - 130.578 (Dec. 2022) )
=
27.5564264
/
199.09
=
13.84%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Vericel (VCEL) has a 3-Year ROIIC % of 13.84 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Vericel and its competitors. This is 22% above median its historical median of 11.39. According to the industry distribution chart, Vericel ranks #492 out of 1324 companies in the Biotechnology industry, placing it in the top 37.2%.
Is Vericel's 3-Year ROIIC % too high?
Vericel's current 3-Year ROIIC % of 13.84 is 22% above median its 10-year median of 11.39. Based on the distribution chart, Vericel ranks #492 out of 1324 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vericel has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's 3-Year ROIIC % compare to NRIX and MLYS?
According to the Biotechnology industry distribution chart, Vericel ranks #492 out of 1324 companies for 3-Year ROIIC %. This puts Vericel in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Vericel and its competitors. Vericel's current 3-Year ROIIC % is 13.84, which is 22% above median its own 10-year median of 11.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $54.29, compared to a current price of $45.07 — trading 17% below its estimated fair value. The current 3-Year ROIIC % is 13.84, which is 22% above median its 10-year median of 11.39. Vericel's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Vericel (VCEL), the current 3-Year ROIIC % is 13.84 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $45.07 is trading 17% below its estimated GF Value™ of $54.29.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
3-Year ROIIC %: 13.84 (22% above median its 10-year median of 11.39)
GF Value™: $54.29 vs. price of $45.07 (17% below fair value)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score
Get the complete analysis for VCEL
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 
